La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Procter & Gamble Health Résultats passés
Passé contrôle des critères 3/6
Procter & Gamble Health has been growing earnings at an average annual rate of 10.1%, while the Pharmaceuticals industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 7.9% per year. Procter & Gamble Health's return on equity is 26.6%, and it has net margins of 18.3%.
Informations clés
10.1%
Taux de croissance des bénéfices
10.1%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 17.5% |
Taux de croissance des recettes | 7.9% |
Rendement des fonds propres | 26.6% |
Marge nette | 18.3% |
Prochaine mise à jour des résultats | 21 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
Ventilation des recettes et des dépenses
Comment Procter & Gamble Health gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Mar 24 | 11,686 | 2,140 | 2,680 | 0 |
31 Dec 23 | 12,370 | 2,267 | 3,092 | 0 |
30 Sep 23 | 12,370 | 2,314 | 2,845 | 0 |
30 Jun 23 | 12,296 | 2,295 | 2,811 | 0 |
31 Mar 23 | 12,243 | 2,408 | 3,030 | 0 |
31 Dec 22 | 11,712 | 2,328 | 2,873 | 0 |
30 Sep 22 | 11,392 | 2,008 | 2,807 | 0 |
30 Jun 22 | 11,144 | 1,925 | 2,776 | 0 |
31 Mar 22 | 11,039 | 1,853 | 2,548 | 0 |
31 Dec 21 | 10,552 | 1,499 | 2,473 | 0 |
30 Sep 21 | 10,176 | 1,729 | 2,372 | 0 |
30 Jun 21 | 10,087 | 1,768 | 2,426 | 0 |
31 Mar 21 | 9,219 | 1,884 | 2,690 | 0 |
31 Dec 20 | 9,308 | 2,191 | 2,577 | 0 |
30 Sep 20 | 9,274 | 1,894 | 2,545 | 0 |
30 Jun 20 | 8,886 | 1,659 | 2,473 | 0 |
31 Mar 20 | 9,237 | 1,645 | 1,171 | 0 |
31 Dec 19 | 9,266 | 1,588 | 1,242 | 0 |
30 Sep 19 | 8,942 | 1,340 | 2,438 | 0 |
30 Jun 19 | 8,952 | 1,394 | 2,424 | 0 |
31 Mar 19 | 8,819 | 1,281 | 2,428 | 0 |
31 Dec 18 | 8,490 | 1,017 | 2,428 | 0 |
30 Sep 18 | 12,290 | 1,349 | 2,914 | 0 |
30 Jun 18 | 12,087 | 1,140 | 2,913 | 0 |
31 Mar 18 | 11,762 | 1,018 | 2,826 | 0 |
31 Dec 17 | 6,981 | 610 | 2,076 | 0 |
30 Sep 17 | 10,523 | 828 | 2,387 | 0 |
30 Jun 17 | 10,088 | 797 | 2,360 | 0 |
31 Mar 17 | 10,177 | 823 | 1,546 | 0 |
31 Dec 16 | 9,926 | 791 | 2,347 | 0 |
30 Sep 16 | 9,810 | 723 | 2,295 | 0 |
30 Jun 16 | 9,681 | 572 | 1,835 | 0 |
31 Mar 16 | 9,589 | 562 | 1,282 | 0 |
31 Dec 15 | 9,383 | 536 | 2,107 | 0 |
30 Sep 15 | 9,148 | 401 | 3,033 | 110 |
30 Jun 15 | 8,798 | 451 | 3,006 | 110 |
31 Mar 15 | 8,712 | 493 | 2,957 | 110 |
31 Dec 14 | 8,662 | 432 | 1,889 | 0 |
30 Sep 14 | 8,544 | 516 | 2,730 | 86 |
30 Jun 14 | 8,409 | 498 | 2,684 | 86 |
31 Mar 14 | 8,082 | 455 | 2,673 | 86 |
31 Dec 13 | 7,965 | 559 | 2,646 | 86 |
30 Sep 13 | 7,599 | 665 | 2,267 | 50 |
Des revenus de qualité: 500126 has high quality earnings.
Augmentation de la marge bénéficiaire: 500126's current net profit margins (18.3%) are lower than last year (19.7%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 500126's earnings have grown by 10.1% per year over the past 5 years.
Accélération de la croissance: 500126's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 500126 had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.3%).
Rendement des fonds propres
ROE élevé: 500126's Return on Equity (26.6%) is considered high.